Trial Profile
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SYMPHONY-1
- Sponsors Epizyme
- 18 Apr 2024 Planned number of patients changed from 568 to 612.
- 18 Apr 2024 Planned End Date changed from 1 Mar 2029 to 27 Apr 2032.
- 18 Apr 2024 Planned primary completion date changed from 1 Mar 2026 to 30 Sep 2029.